News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Blood test could pick up genetic echoes of lifestyle risk for cancer
A blood test could one day uncover the genetic ‘echoes’ from past activity such as smoking which could increase a person’s chance of developing cancer years later
Scientists discover way to target rare breast cancer mutation
UK scientists have identified a drug to target a rare breast cancer mutation that helps drive the disease in around 900 of the 50,000 new cases of breast cancer diagnosed in the UK each year.
ICR supporters take on the Berlin Marathon
Supporters of The Institute of Cancer Research, London, raised more than £7,000 at the Berlin Marathon for research into cancer.
Professor Paul Workman appointed as ICR Chief Executive
Professor Paul Workman has been appointed as Chief Executive and President of The Institute of Cancer Research, London, on a permanent basis.
New research leader pledges three-pronged attack on cancer evolution and drug resistance
Professor Paul Workman sets out his vision for cancer drug discovery as he is appointed Chief Executive of The Institute of Cancer Research, London
Structural study reveals clues of cancer-causing protein
Advanced modelling techniques have mapped the structure of a key protein for the development of the nervous system – and cancer, a new study reveals.
Genetic testing could improve breast cancer prevention
Screening women for a wide range of known genetic risk factors could improve strategies for breast cancer prevention, a new analysis shows.
Prostate cancer: entering a golden age of research
Oncologists are hailing this as the ‘golden age of prostate cancer research’ after new prostate cancer drugs reached the clinic. The ICR has played a major role in developing four new drugs that have been shown as effective in later-phase trials.
BRCA-targeting drugs could treat prostate cancer, leading expert says
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert said today.
How the ICR drove the science behind pioneering cancer drug
Olaparib is set to become the first cancer drug for an inherited genetic fault. Here is the story of our crucial role in its development.
Statement in response to the European Medicines Agency's recommendation for approval of olaparib
The Institute of Cancer Research, London, is issuing the following statement from Professor Alan Ashworth, whose work underpinned the development of olaparib.
Cancer drug discovery system is broken, global summit hears
Paul Workman of the ICR calls for major changes to restock pipeline with innovative cancer treatments.
